Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06625775
Registration number
NCT06625775
Ethics application status
Date submitted
1/10/2024
Date registered
3/10/2024
Date last updated
1/10/2026
Titles & IDs
Public title
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Query!
Scientific title
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)
Query!
Additional trial identifiers [1]
0
0
2024-519445-29-00
Query!
Additional trial identifiers [2]
0
0
TBBO10203-101
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Solid Tumor, Adult
0
0
Query!
Metastatic Breast Cancer
0
0
Query!
Advanced Breast Cancer
0
0
Query!
HER2 Mutation-Related Tumors
0
0
Query!
HER2-positive Metastatic Breast Cancer
0
0
Query!
KRAS Mutant Metastatic Colorectal Cancer
0
0
Query!
Metastatic Lung Cancer
0
0
Query!
Metastatic Colorectal Cancer
0
0
Query!
Advanced Lung Cancer
0
0
Query!
HR-positive, HER2-negative Advanced Breast Cancer
0
0
Query!
HER2-positive Advanced Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Cancer
0
0
0
0
Query!
Bowel - Back passage (rectum) or large bowel (colon)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
Treatment: Drugs - BBO-10203
Treatment: Drugs - Trastuzumab
Treatment: Drugs - Fulvestrant
Treatment: Drugs - Ribociclib
Treatment: Drugs - FOLFOX
Treatment: Drugs - Bevacizumab
Experimental: BBO-10203 - Participants enrolled in this cohort will receive BBO-10203 tablets orally (different dose levels will be evaluated) once daily as monotherapy. This cohort will enroll patients with HER2-positive advanced breast cancer, HR-positive HER2-negative advanced breast cancer, advanced colorectal cancer, and advanced lung cancer.
Experimental: BBO-10203 + Trastuzumab - Participants enrolled in this cohort will receive BBO-10203 tablets orally in combination with trastuzumab. This cohort will enroll patients with HER2-positive advanced breast cancer.
Experimental: BBO-10203 + Fulvestrant - Participants enrolled in this cohort will receive BBO-10203 tablets orally in combination with fulvestrant. This cohort will enroll patients with HR-positive, HER2-negative advanced breast cancer.
Experimental: BBO10203 + Fulvestrant + Ribociclib - Participants enrolled in this cohort will receive BBO-10203 tablets orally in combination with fulvestrant and ribociclib as determined in the dose escalation. This cohort will enroll patients with HR-positive, HER2-negative advanced breast cancer.
Experimental: BBO10203 + FOLFOX + Bevacizumab - Participants enrolled in this cohort will receive BBO-10203 tablets orally in combination with FOLFOX and bevacizumab. This cohort will enroll patients with KRAS-mutant advanced colorectal cancer.
Treatment: Drugs: BBO-10203
Participants will receive assigned dose of BBO-10203 orally once daily
Treatment: Drugs: Trastuzumab
Participants will receive trastuzumab as infusion or subcutaneous injection every 21 days
Treatment: Drugs: Fulvestrant
Patients will receive Fulvestrant as an intramuscular injection every 28 days (additional dose on C1D15)
Treatment: Drugs: Ribociclib
Patients will receive Ribociclib orally once a day (21 days on treatment, 7 days off)
Treatment: Drugs: FOLFOX
Patients will receive FOLFOX as infusion every 14 days
Treatment: Drugs: Bevacizumab
Patients will receive bevacizumab as infusion every 28 days
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Description of the comparator or control
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Determination of maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of BBO-10203 as a single agent
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to approximately 5 years
Query!
Primary outcome [2]
0
0
Percentage of patients with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Up to approximately 5 years
Query!
Primary outcome [3]
0
0
Recommended BBO-10203 dose in combination with trastuzumab, fulvestrant +/- ribociclib, and FOLFOX + bevacizumab
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Up to approximately 5 years
Query!
Secondary outcome [1]
0
0
Clinical benefit rate (CBR) as assessed by RECIST v1.1.
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to approximately 5 years
Query!
Secondary outcome [2]
0
0
Duration of response (DOR) as assessed by RECIST v1.1.
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Up to approximately 5 years
Query!
Secondary outcome [3]
0
0
Progression-free survival (PFS) as assessed by RECIST v1.1
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Up to approximately 5 years
Query!
Secondary outcome [4]
0
0
Overall survival (OS)
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Up to approximately 5 years
Query!
Secondary outcome [5]
0
0
Area under the concentration-time curve (AUC
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Predose (within 30 minutes) of C1D1 until up to approximately 5 years
Query!
Secondary outcome [6]
0
0
Maximum plasma drug concentration (Cmax)
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Predose (within 30 minutes) of C1D1 until up to approximately 5 years
Query!
Secondary outcome [7]
0
0
Time for maximum plasma drug concentration (Tmax)
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Predose (within 30 minutes) of C1D1 until up to approximately 5 years
Query!
Secondary outcome [8]
0
0
Objective response rate (ORR) as assessed by RECIST v1.1 for patients with measurable disease
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Up to approximately 5 years
Query!
Eligibility
Key inclusion criteria
* Locally advanced and unresectable or metastatic HER2-positive advanced breast cancer (aBC), HR-positive/HER2-negative advanced breast cancer, KRAS mutant advanced colorectal cancer (aCRC), or KRAS mutant advanced non-small cell lung cancer (aNSCLC)
* Measurable disease by RECIST v1.1 (except for HR-positive HER2-negative aBC where evaluable bone-only disease is permitted)
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
* Adequate LVEF assessed by ECHO or MUGA (BBO-10203 + Trastuzumab cohorts only)
* Stable brain metastases
* Patients with HER2-positive aBC: Must have had at least 2 prior lines of anti-HER2-directed therapy. Only 1 prior line is acceptable where there is no other regionally available standard of care (SoC)
* Monotherapy Cohort patients with HR-positive, HER2-negative aBC, KRAS mutant aCRC or aNSCLC: Must have progression on, or disease recurrence after at least one line of SOC treatment or in the opinion of the investigator, would be unlikely to tolerate or derive clinically meaningful benefit from SoC therapy
* BBO-10203 + Fulvestrant combination cohort patients with HR-positive, HER2-negative aBC: confirmed PIK3CA mutation, must have been treated with a CDK4/6i
* BBO-10203 + Fulvestrant + ribociclib combination cohort patients with HR-positive, HER2-negative aBC: confirmed PIK3CA mutation, no prior systemic therapy in the aBC setting permitted
* BBO-10203 + FOLFOX + Bevacizumab combination cohort patients with KRAS mutant aCRC: One prior line of irinotecan-containing therapy for locally advanced or metastatic CRC is allowed but not required
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
* Patients with KRAS mutant aCRC who have KRAS G12R mutation, BRAFV600E mutation, HER2amp, or dMMR/MSI-H tumors
* Patients with KRAS mutant aNSCLC who have KRAS G12R mutation, or tumors with other targetable driver mutations (eg, EGFR, anaplastic lymphoma kinase, ROS1/BRAF/RET/MET/EGFR exon20 insertion/NTRK/HER2)
* Patients with untreated and/or non-stable brain metastases
Other inclusion/exclusion criteria are specified in the protocol
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
29/10/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/11/2028
Query!
Actual
Query!
Sample size
Target
392
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Scientia Clinical Research - Randwick
Query!
Recruitment hospital [2]
0
0
Peter MacCallum Cancer Centre - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [2]
0
0
3000 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Indiana
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Massachusetts
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Missouri
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New York
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Tennessee
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Texas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Washington
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Wisconsin
Query!
Country [11]
0
0
Brazil
Query!
State/province [11]
0
0
Rio Grande do Norte
Query!
Country [12]
0
0
Brazil
Query!
State/province [12]
0
0
Rio Grande do Sul
Query!
Country [13]
0
0
Brazil
Query!
State/province [13]
0
0
São Paulo
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Occitanie
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Paris
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Pays de la Loire Region
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Bordeaux
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Lyon
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Île-de-France Region
Query!
Country [20]
0
0
South Korea
Query!
State/province [20]
0
0
Seoul
Query!
Country [21]
0
0
Spain
Query!
State/province [21]
0
0
Catalonia
Query!
Country [22]
0
0
Spain
Query!
State/province [22]
0
0
Madrid
Query!
Country [23]
0
0
Spain
Query!
State/province [23]
0
0
Barcelona
Query!
Country [24]
0
0
Spain
Query!
State/province [24]
0
0
Lleida
Query!
Country [25]
0
0
Spain
Query!
State/province [25]
0
0
Valencia
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Ka:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06625775
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
BBOT (BridgeBio Oncology Therapeutics)
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
650-405-8440
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06625775
Download to PDF